JP2015501808A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501808A5
JP2015501808A5 JP2014543550A JP2014543550A JP2015501808A5 JP 2015501808 A5 JP2015501808 A5 JP 2015501808A5 JP 2014543550 A JP2014543550 A JP 2014543550A JP 2014543550 A JP2014543550 A JP 2014543550A JP 2015501808 A5 JP2015501808 A5 JP 2015501808A5
Authority
JP
Japan
Prior art keywords
solid oral
oral pharmaceutical
compound
formulation
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501808A (ja
JP6216325B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066185 external-priority patent/WO2013078264A1/en
Publication of JP2015501808A publication Critical patent/JP2015501808A/ja
Publication of JP2015501808A5 publication Critical patent/JP2015501808A5/ja
Application granted granted Critical
Publication of JP6216325B2 publication Critical patent/JP6216325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543550A 2011-11-23 2012-11-21 医薬製剤 Active JP6216325B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563229P 2011-11-23 2011-11-23
US61/563,229 2011-11-23
PCT/US2012/066185 WO2013078264A1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017182214A Division JP2018035171A (ja) 2011-11-23 2017-09-22 医薬製剤

Publications (3)

Publication Number Publication Date
JP2015501808A JP2015501808A (ja) 2015-01-19
JP2015501808A5 true JP2015501808A5 (enExample) 2016-01-14
JP6216325B2 JP6216325B2 (ja) 2017-10-18

Family

ID=47501412

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543550A Active JP6216325B2 (ja) 2011-11-23 2012-11-21 医薬製剤
JP2017182214A Pending JP2018035171A (ja) 2011-11-23 2017-09-22 医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017182214A Pending JP2018035171A (ja) 2011-11-23 2017-09-22 医薬製剤

Country Status (38)

Country Link
US (4) US9387208B2 (enExample)
EP (2) EP3449911B8 (enExample)
JP (2) JP6216325B2 (enExample)
KR (1) KR102091295B1 (enExample)
CN (2) CN103945831A (enExample)
AR (1) AR088936A1 (enExample)
AU (1) AU2012340759C1 (enExample)
BR (1) BR112014011981B8 (enExample)
CA (1) CA2856406C (enExample)
CL (1) CL2014001337A1 (enExample)
CO (1) CO6940426A2 (enExample)
CY (1) CY1121421T1 (enExample)
DK (1) DK2782557T3 (enExample)
EA (1) EA025389B1 (enExample)
EC (1) ECSP23034537A (enExample)
ES (2) ES2695099T3 (enExample)
GT (1) GT201400100A (enExample)
HR (1) HRP20181896T1 (enExample)
HU (1) HUE040370T2 (enExample)
IL (1) IL232305B (enExample)
JO (1) JO3493B1 (enExample)
LT (1) LT2782557T (enExample)
MA (1) MA35716B1 (enExample)
MX (1) MX353446B (enExample)
MY (1) MY172729A (enExample)
PE (1) PE20141994A1 (enExample)
PH (1) PH12014501157A1 (enExample)
PL (1) PL2782557T3 (enExample)
PT (1) PT2782557T (enExample)
RS (1) RS58048B1 (enExample)
SG (1) SG11201401260QA (enExample)
SI (1) SI2782557T1 (enExample)
SM (1) SMT201800595T1 (enExample)
TN (1) TN2014000145A1 (enExample)
TW (1) TWI649098B (enExample)
UA (1) UA115039C2 (enExample)
WO (1) WO2013078264A1 (enExample)
ZA (1) ZA201402418B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
CN103945831A (zh) 2011-11-23 2014-07-23 诺华股份有限公司 医药制剂
PT3302565T (pt) 2015-06-04 2020-01-14 Pfizer Formas de dosagem sólida de palbociclib
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
FI3463345T3 (fi) 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
CN114181197B (zh) * 2022-02-16 2022-05-06 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
TR2022009483A2 (tr) * 2022-06-08 2023-12-21 Abdi̇ İbrahi̇m İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Palbosiklib içeren bir farmasötik bileşim.
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib
WO2025262137A1 (en) * 2024-06-21 2025-12-26 Nanoform Finland Oyj Formulations comprising crystalline nanosized encorafenib

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
WO1997008950A1 (en) 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EE9900527A (et) 1997-05-22 2000-06-15 G.D. Searle & Co. Substitueeritud pürasoolid kui p38 kinaasi inhibiitorid
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
EP1239831B1 (en) 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20090149469A1 (en) 2004-01-09 2009-06-11 Carlos Garcia-Echeverria Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
EP1919460A2 (en) * 2005-08-22 2008-05-14 Novartis AG Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CA2663366C (en) 2006-10-02 2012-02-07 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
CA2695114A1 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
CA2699301A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EA201001456A1 (ru) 2008-03-21 2011-06-30 Новартис Аг Новые гетероциклические соединения и их применение
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DK2324008T3 (da) 2008-07-24 2012-07-23 Nerviano Medical Sciences Srl Diarylpyrazol som protein kinase inhibitorer
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
CN102227421A (zh) 2008-09-29 2011-10-26 贝林格尔.英格海姆国际有限公司 抗增殖化合物
DK2346495T4 (da) * 2008-10-07 2023-08-28 Kudos Pharm Ltd Farmaceutisk formulering 514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
WO2010070060A1 (en) 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN102947290B (zh) 2010-01-27 2015-05-27 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
SG184243A1 (en) 2010-03-30 2012-10-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
US20140093565A1 (en) 2011-03-21 2014-04-03 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof
US20140113919A1 (en) 2011-06-14 2014-04-24 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
CN103945831A (zh) 2011-11-23 2014-07-23 诺华股份有限公司 医药制剂
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний

Similar Documents

Publication Publication Date Title
JP2015501808A5 (enExample)
JP6216325B2 (ja) 医薬製剤
US9907789B2 (en) Sustained-release preparation
ES2674811T3 (es) Composiciones estables de fesoterodina
KR101093781B1 (ko) ｐＨ조절제를 함유하는 목시플록사신 고형 조성물
EP2839829A1 (en) Sustained release tablet containing levodropropizine and method for preparing same
JP2021518422A (ja) レナリドミドを含む医薬組成物
JP2022140430A (ja) リバーロキサバン含有錠剤
HK40005622A (en) Pharmaceutical formulations
NZ623628B2 (en) Solid oral pharmaceutical formulations comprising amorphous (S)-methyl (1- ((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropy1-1H-pyrazo1-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (Compound A)
TW201729814A (zh) 固形製劑
HK1197024B (en) Pharmaceutical formulations
NZ713151B2 (en) Sustained-release formulations of colchicine and methods of using same
NZ713151A (en) Sustained-release formulations of colchicine and methods of using same